What this trial means for you
This study is recruiting now at 1 US site. It's studying see the official record for obesity, body composition.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria 1. Age ≥ 18 years old at time of signing informed consent 2. Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment a. Potential participants switching GLP1-RA therapies due to inadequate response to a prior treatment will be eligible for enrollment 3. Able to provide informed consent Exclusion Criteria 1. Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months 2. BMI \<25 kg/m2 at the time of screening 3. Unable to participate in a regular physical exercise program 4. Implanted pacemaker 5. Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study
Study sites by state
Massachusetts
- Diabetes Research Center — Boston · Recruiting now
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)